

A global pharmaceutical company that promotes health and welfare for all



www.celltrion.com/en-us

# Celltrion, Inc.

CEO Kee Woo Sung

Location 23 Academy-ro, Yeonsu-gu, Incheon Metropolitan City

Specialty Biosimilars, New Drugs, Small Molcules

Tel / Fax / E-mail T. 82-32-850-5000 E. Contact@celltrion.com Celltrion, Inc. is a leading Korean biopharmaceutical company that launched the world's very first antibody biosimilar product, Remsima<sup>®</sup>. As one of the first companies to chart the Korean biopharmaceutical sector, Celltrion pioneered many previously unexplored areas and evolved into one of the leaders in the biosimilar development and manufacturing sector with numerous milestone achievements. The company now plans to keep the momentum and continue the legacy as it ventures into new business areas such as small molecule pharmaceuticals and Ubiquitous-healthcare system with unique Celltrion approaches.

# Main Products



## Biopharmaceutical

Product	Reference Product	INN	Indications
Remsima SC	-	Infliximab	Rheumatoid Arthritis
Remsima / Inflectra	Remicade	Infliximab	Rheumatoid Arthritis, Ankylsoing Spondylitis, Ulcerative Colitis, Crohn's Disease, Psoriasis
Truxima	Rituxan	Non-Hodgkin's Lymphoma, Chronic Lymphocytic Rituximab Rheumatoid Arthritis, Granulomatosis with Poly Microscopic Polyangiitis	
Herzuma	Herceptin	Trastuzumab	HER2-Positive Metastatic Breast Cancer, Early Breast Cancer, Metastatic Gastric Cancer

Herzuma

#### Small molecule

Product	Ingredient	Indications
Linezolid	Linezolid	Pneumonia, Skin and Skin Structure Infections, Vancomycin-resistant Enterococcus faecium Infections

## **R&D** Pipeline

### **Antibody Biosimilars**

Project	INN	Original	Indications	Status
CT-P39	Omalizumab	XOLAR®	Asthma, Urticaria	Research
CT-P17	Adalimumab	HUMIRA®	Rheumatoid arthritis, Psoriatic arthritis, IBD	Phase3
CT-P16	Bevacizumab	AVASTIN®	Metastatic Colorectal Cancer, Metastatic Breast Cancer, NSCLC	Phase3

#### **New Antibodies**

Project	Indications	Status
CT-P59	COVID-19	Research
CT-P27	Pandemic Seasonal influenza	Phase2

IMDs		
Project	Indications	Status
CT-G20	Cardiomyopathy	Clinical trial